Biora Therapeutics Celebrates Recognition for Research
Biora Therapeutics, Inc. (NASDAQ: BIOR), a forward-thinking biotech firm focused on innovative therapeutic delivery solutions, has announced that its latest research has earned a prestigious award at an upcoming healthcare conference. The American College of Gastroenterology (ACG) Annual Scientific Meeting, set for late October, will feature Biora’s groundbreaking work shining a light on their commitment to enhancing patient care.
A Glimpse into the ACG Annual Scientific Meeting 2024
Every year, the ACG Annual Scientific Meeting attracts experts in the field of gastroenterology, providing a platform to discuss the latest advancements. This year, the event will unfold in Philadelphia, from October 25 to 30, 2024. Biora’s research has been recognized notably as it prepares for a poster presentation during this esteemed gathering, which is certainly a testament to its significance in the medical community.
Prestigious Award Recognition
Highlighting the excellence of its submission, Biora Therapeutics is thrilled to share that it has received a Presidential Poster Award. This accolade is granted to less than 5% of accepted abstracts each year, reinforcing Biora's significant contributions to innovative research methods in therapeutic delivery. The hard work and determination to improve patient outcomes are hallmarks of Biora's culture, and such recognition underscores their efforts.
Details of the Presentation
Attendees of the ACG meeting can anticipate detailed insights from Biora's presentation, identified as Poster Number P4275. The event is scheduled for October 29, 2024, from 10:30 AM to 4:00 PM ET. The lead author of the poster, Brian Feagan, MD, FRCPC, will be sharing valuable research findings that highlight the advances made in therapeutic techniques in gastroenterology.
Research Details Under Embargo
The findings presented by Biora are under strict embargo until October 27 at 12:00 ET. This emphasizes the importance of sharing research responsibly and highlights the ethical standards upheld by Biora Therapeutics. Following the presentation, more details will be available for those interested in learning about the innovative approaches Biora is developing.
About Biora Therapeutics
At the forefront of clinical research, Biora Therapeutics is dedicated to creating solutions that enhance therapeutic delivery systems. The company is developing two advanced platforms: the NaviCap™ and BioJet™. The NaviCap™ platform focuses on the colon-targeted treatment of inflammatory bowel disease (IBD), improving therapeutic efficacy by delivering medications directly to affected areas. Meanwhile, the BioJet™ platform seeks to revolutionize the delivery of large molecules orally, enabling a needle-free approach to manage chronic diseases effectively.
Stay Connected
For those wishing to explore Biora Therapeutics further, more information can be found on their official website and through various social media channels. Engaging with Biora online allows for ongoing updates regarding their research developments and contributions to the biotech landscape.
Frequently Asked Questions
What is the significance of the ACG Annual Scientific Meeting?
The ACG meeting is a key event for gastroenterology professionals to exchange knowledge and present research.
What does the Presidential Poster Award signify?
This award recognizes high-quality research submissions, highlighting innovation in the field.
Who is Brian Feagan, and what role does he play?
Brian Feagan, MD, FRCPC, is the presenting author of Biora's research at the ACG meeting.
How does Biora's NaviCap™ platform work?
NaviCap™ is designed to target treatments directly to the colon for better therapeutic impact in IBD patients.
Where can I find more updates about Biora Therapeutics?
Updates can be found on Biora's website and their official social media platforms.
